Publication: Dry eye disease compounds currently under evaluation in clinical trials
Loading...
Official URL
Full text at PDC
Publication Date
2014
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Real Academia Nacional de Farmacia
Citations
Exportar
Abstract
Dry eye syndrome is a common disorder provoking changes in tear quantity and composition being the most common ophthalmic manifestation of systemic inflammatory diseases. Untreated dry eye could cause increased risk of ocular infection, corneal ulcer and blindness. Only a few drugs are authorized so far for the treatment of dry eye disease and the possibilities of evolution in this sector are immense. Accordingly, the future tendency is towards the development of drugs to control the inflammation or stimulate the mucin and tear secretion. A significant number of new potential solutions are under development or placed in the pharmaceutical pipeline, promising better results and lesser side effects, but still leaving unattended the main causes of the disease. In this article, we review the corresponding literature, recent clinical trials data and patents concerning future pharmaceutical compounds for dry eye disease treatment, presenting the new strategic movements of the pharmaceutical industry.
El síndrome de ojo seco es un trastorno bastante común, provocando cambios en la cantidad y la composición de lágrima, siendo la manifestación oftálmica más común de enfermedades inflamatorias sistémicas. El ojo seco no tratado puede provocar un aumento del riesgo de infección ocular, úlceras corneales y en casos extremos ceguera. Actualmente sólo unos pocos fármacos están autorizados para el tratamiento de la enfermedad y las posibilidades de evolución en este sector son inmensas. La tendencia del futuro está dirigida hacia el desarrollo de fármacos que controlan la inflamación o estimulan la secreción de las mucinas y de las lágrimas. Un número significativo de nuevos compuestos están en desarrollo o ya están en ensayos clínicos, con aparentes mejores resultados y efectos secundarios menos adversos, pero una vez más dejando desatendidas las principales causas de la enfermedad. En este artículo revisamos la literatura correspondiente, los últimos datos de los ensayos clínicos y las patentes relativas a futuros compuestos farmacéuticos para el tratamiento de la enfermedad del ojo seco, desvelando los nuevos movimientos estratégicos de la industria farmacéutica.
El síndrome de ojo seco es un trastorno bastante común, provocando cambios en la cantidad y la composición de lágrima, siendo la manifestación oftálmica más común de enfermedades inflamatorias sistémicas. El ojo seco no tratado puede provocar un aumento del riesgo de infección ocular, úlceras corneales y en casos extremos ceguera. Actualmente sólo unos pocos fármacos están autorizados para el tratamiento de la enfermedad y las posibilidades de evolución en este sector son inmensas. La tendencia del futuro está dirigida hacia el desarrollo de fármacos que controlan la inflamación o estimulan la secreción de las mucinas y de las lágrimas. Un número significativo de nuevos compuestos están en desarrollo o ya están en ensayos clínicos, con aparentes mejores resultados y efectos secundarios menos adversos, pero una vez más dejando desatendidas las principales causas de la enfermedad. En este artículo revisamos la literatura correspondiente, los últimos datos de los ensayos clínicos y las patentes relativas a futuros compuestos farmacéuticos para el tratamiento de la enfermedad del ojo seco, desvelando los nuevos movimientos estratégicos de la industria farmacéutica.
Description
Revista de O.A.
UCM subjects
Unesco subjects
Keywords
Citation
1. Fauchais AL, Martel C, Vidal E. (Epidemiology and physiopathogy of Sjogren's syndrome). Rev Prat. 62(2), 218-20 (2012).
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 5(2), 93- 107 (WorkShop in Epidemiology of Dry Eye 2007).
3. Abusharha AA, Pearce EI. The Effect of Low Humidity on the Human Tear Film. Cornea. (2012).
4. Portello JK, Rosenfield M, Bababekova Y, et al. Computer-related visual symptoms in office workers. Ophthalmic Physiol Opt. 32(5), 375-82 (2012).
5. Thorud HM, Helland M, Aaras A, et al. Eye-related pain induced by visually demanding computer work. Optom Vis Sci. 89(4), E452-64 (2012).
6. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 5(2), 75-92 (Dry Eye WorkShop Definition and Classification 2007).
7. Linsen C, Missotten L. Physiology of the lacrimal system. Bull Soc Belge Ophtalmol. 238 35-44 (1990).
8. Dilly PN. Structure and function of the tear film. Adv Exp Med Biol. 350 239-47 (1994).
9. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea. 23(8), 762-70 (2004).
10. Kastelan S, Lukenda A, Salopek-Rabatic J, et al. Dry eye symptoms and signs in long-term contact lens wearers. Coll Antropol. 37 Suppl 1 199-203 (2013).
11. Lemp MA. Epidemiology and classification of dry eye. Adv Exp Med Biol. 438 791-803 (1998).
12. Glasson MJ, Stapleton F, Keay L, et al. Differences in clinical parameters and tear film of tolerant and intolerant contact lens wearers. Invest Ophthalmol Vis Sci. 44(12), 5116-24 (2003).
13. Donate J, Benitez del Castillo JM, Fernandez C, et al. (Validation of a questionnaire for the diagnosis of dry eye). Arch Soc Esp Oftalmol. 77(9), 493-500 (2002).
14. Methodologies to diagnose and monitor dry eye disease. 2007 Report of the International Dry Eye Workshop. The Ocular Surface 2007. 2007.
15. Savini G, Prabhawasat P, Kojima T, et al. The challenge of dry eye diagnosis. Clin Ophthalmol. (2008).
16. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 23(3), 272-85 (2004).
17. Albietz JM, Bruce AS. The conjunctival epithelium in dry eye subtypes: effect of preserved and non-preserved topical treatments. Curr Eye Res. 22(1), 8-18 (2001).
18. Yaguchi S, Ogawa Y, Kamoi M, et al. Surgical management of lacrimal punctal cauterization in chronic GVHD-related dry eye with recurrent punctal plug extrusion. Bone Marrow Transplant. (2012).
19. Korb DR, Greiner JV, Glonek T, et al. Effect of periocular humidity on the tear film lipid layer. Cornea. 15(2), 129-34 (1996).
20. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 5(2), 163-78 (2007).
21. Luo L, Li DQ, Corrales RM, et al. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens. 31(5), 186-93 (2005).
22. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 45(12), 4293-301 (2004).
23. Yang CQ, Sun W, Gu YS. A clinical study of the efficacy of topical corticosteroids on dry eye. J Zhejiang Univ Sci B. 7(8), 675-8 (2006).
24. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 107(4), 631-9 (2000).
25. Spies CM, Gaber T, Hahne M, et al. Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. Immunol Lett. 131(1), 24-32 (2010).
26. AL-2178. ClinicalTrials.gov Identifier: NCT00471419 http://clinicaltrials.gov/ct2/show/NCT00471419?term=AL-2178+Rimexolone&rank=1. (2008).
27. Anglade E, Yatscoff R, Foster R, et al. Next-generation calcineurin inhibitors for ophthalmic indications. Expert Opin Investig Drugs. 16(10), 1525-40 (2007).
28. LX214. ClinicalTrials.gov Identifier: NCT00851734 http://clinicaltrials.gov/ct2/show/NCT00851734?term=LX214&rank=1. (2012).
29. Uckun FM, Malavia R, Sudbeck EA. JAK-3 inhibitors for treating allergic disorders. US20006080747 (2000)
30. Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial. Ophthalmology. 119(7), 1328-35 (2012).
31. Huang JF, Yafawi R, Zhang M, et al. Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease. Ophthalmology. 119(7), e43-50 (2012).
32. Rosenberg ES, Asbell PA. Essential fatty acids in the treatment of dry eye. Ocul Surf. 8(1), 18-28 (2010).
33. Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gammalinolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea. 22(2), 97-101 (2003).
34. Creuzot C, Passemard M, Viau S, et al. (Improvement of dry eye symptoms with polyunsaturated fatty acids). J Fr Ophtalmol. 29(8), 868-73 (2006).
35. Creuzot-Garcher C, Baudouin C, Labetoulle M, et al. (Efficacy assessment of Nutrilarm(R), a per os omega-3 and omega-6 polyunsaturated essential fatty acid dietary formulation versus placebo in patients with bilateral treated moderate dry eye syndrome). J Fr Ophtalmol. 34(7), 448-55 (2011).
36. Brignole-Baudouin F, Baudouin C, Aragona P, et al. A multicentre, doublemasked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol. 89(7), e591-7 (2011).
37. Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol. 22(4), 279-82 (2011).
38. Steven P, Cursiefen C. (Anti-inflammatory treatment in dry eye disease). Klin Monbl Augenheilkd. 229(5), 500-5 (2012).
39. Axtell RC, Steinman L, Han MH, et al. Markers for determination of patient responsiveness. US20110250206, US20110243893 (2011) .
40. Dhimolea E. Canakinumab. MAbs. 2(1), 3-13 (2010).
41. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2(52), 52ra72 (2010).
42. Patel DD, Lee DM, Kolbinger F, et al. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. (2012).
43. Cumberlidge G, Lama T, Meerovitch K. Beta-turn peptidomimetic cyclic compounds for treating dry eye. US20128293713 (2012).
44. Wang ZX, Sun XG. (The effect of nerve growth factor on proliferation and expression of mucin gene in human conjunctival goblet cells). Zhonghua Yan Ke Za Zhi. 43(10), 928-31 (2007).
45. Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res. 93(4), 503-12 (2011).
46. Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 7 1275-85 (2013).
47. Boltralik JJ. Anti-inflammatory compounds for ophthalmic use. US19955446177 (1995).
48. Mulki L, Foster CS. Difluprednate for inflammatory eye disorders. Drugs Today (Barc). 47(5), 327-33 (2011).
49. Viiri J, Jauhonen HM, Kauppinen A, et al. Cis-urocanic acid suppresses UV-Binduced interleukin-6 and -8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro. Mol Vis. 15 1799-805 (2009).
50. Jauhonen HM, Kauppinen A, Paimela T, et al. Cis-urocanic acid inhibits SAPK/JNK signaling pathway in UV-B exposed human corneal epithelial cells in vitro. Mol Vis. 17 2311-7 (2011).
51. Sosne G, Crockford D. Methods and compositions for stabilizing polypeptides. WO2008108927 (2008)
52. Golstein AL, Sosne G. Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (Tb4), analogues, isoforms and other derivatives US20110020449 (2011).
53. Philp D, Kleinman HK. Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci. 1194 81-6 (2010).
54. Sosne G, Qiu P, Ousler GW, 3rd, et al. Thymosin beta4: a potential novel dry eye therapy. Ann N Y Acad Sci. 1270 45-50 (2012).
55. Sosne G, Crockford D, Finkelstein JJ, et al., editors. Single-Center Study Evaluating the Safety and Efficacy of 0.1% Tβ4 Ophthalmic Solution Compared to Vehicle on the Signs and Symptoms of Dry Eye in the Controlled Adverse Environment (CAE) Model (abstract) 2012 ARVO E-Abstract 577/A45.
56. Belimumab. ClinicalTrials.gov Identifier: NCT01160666 http://clinicaltrials.gov/ct2/show/NCT01160666?term=Belimumab+Sjogren&rank=1.
(2012).
57. Cornec D, Saraux A, Devauchelle-Pensec V, et al. The future of B cell-targeted therapies in Sjogren's syndrome. Immunotherapy. 5(6), 639-46 (2013).
58. Rituximab. ClinicalTrials.gov Identifier: NCT00740948 http://clinicaltrials.gov/ct2/show/NCT00740948?term=Rituximab+Sjogren&rank=1.
(2013).
59. Moerman RV, Arends S, Meiners PM, et al. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis. 73(2), 472-4 (2014).
60. Bartels PS. Use of loteprednol etabonate for the treatment of dry eye. WO2005094836A2 (2005).
61. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 92(4), 455-9 (2008).
62. Sheppard JD, Scoper SV, Samudre S. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease. J Ocul Pharmacol Ther. 27(1), 23-7 (2011).
63. Wan PX, Wang XR, Song YY, et al. (Study on the treatment of dry eye with Loteprednol Etabonate). Zhonghua Yan Ke Za Zhi. 48(2), 142-7 (2012).
64. Ogawa T, Watanabe N, Okumura Y. Method for preventing or treating dry eye or disease caused therefrom. US19985830913 (1998)
65. Munakata W, Liu Q, Shimoyama T, et al. Ecabet sodium attenuates reactive oxygen species produced by neutrophils after priming with bacterial lipopolysaccharides. Luminescence. 18(6), 330-3 (2003).
66. Shimoyama T, Fukuda Y, Fukuda S, et al. Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. J Gastroenterol. 31 Suppl 9 59-62 (1996).
67. Zhang JZ, Cavet ME, VanderMeid KR, et al. BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells. Mol Vis. 15 2606-16 (2009).
68. Vollmer TR, Stockhausen A, Zhang JZ. Anti-inflammatory effects of mapracorat, a novel selective glucocorticoid receptor agonist, is partially mediated by MAP kinase phosphatase-1 (MKP-1). J Biol Chem. 287(42), 35212-21 (2012).
69. Schoepe S, Schacke H, Bernd A, et al. Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand- induced skin atrophy. Skin Pharmacol Physiol. 23(3), 139-51 (2010).
70. AL-43546. ClinicalTrials.gov Identifier: NCT00760045 http://clinicaltrials.gov/ct2/show/NCT00760045?term=AL43546&rank=1. (2010).
71. Caballero-Velazquez T, Sanchez-Abarca LI, Gutierrez-Cosio S, et al. The novel combination of sirolimus and bortezomib prevents graft-versus- host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation. Haematologica. 97(9), 1329-37 (2012).
72. Dor JP, Nivaggioli T, Reilly P, et al. mTOR pathway inhibitors for treating ocular disorders. WO2010129622 (2010).
73. Cao GF, Liu Y, Yang W, et al. Rapamycin sensitive mTOR activation mediates nerve growth factor (NGF) induced cell migration and pro-survival effects against hydrogen peroxide in retinal pigment epithelial cells. Biochem Biophys Res Commun. 414(3), 499-505 (2011).
74. Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 3(1), 32 (2013).
75. Bowman ML, Hosseini K, Pham S, et al. Non-steroidal anti-inflammatory ophthalmic compositions. WO2010102192 (2010).
76. Urech DM. Functionalized polypeptides. WO2010006454 (2010).
77. Ottiger M, Thiel MA, Feige U, et al. Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Invest Ophthalmol Vis Sci. 50(2), 779-86 (2009).
78. Thiel MA, Wild A, Schmid MK, et al. Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology. 120(7), 1403-8 (2013).
79. Choi SM, Seo MJ, Lee YG, et al. Effects of DA-6034, a flavonoid derivative, on mucin-like glycoprotein and ocular surface integrity in a rabbit model. Arzneimittelforschung. 59(10), 498-503 (2009).
80. Seo MJ, Kim JM, Lee MJ, et al. The therapeutic effect of DA-6034 on ocular inflammation via suppression of MMP-9 and inflammatory cytokines and activation of the MAPK signaling pathway in an experimental dry eye model. Curr Eye Res. 35(2), 165-75 (2010).
81. Lan W, Petznick A, Heryati S, et al. Nuclear Factor-kappaB: central regulator in ocular surface inflammation and diseases. Ocul Surf. 10(3), 137-48 (2012).
82. Gjorstrup P. Compositions and methods for the treatment of ophthalmic conditions. US2009011824 (2009).
83. Therapeutics C. Developing therapies for critical unmet medical needs. RX 10045 - Dry Eye and Allergic Conjunctivitis. http://www.celtictherapeutics.com/RX100452012.
84. Pharmaceuticals R. RX-10045 http://www.resolvyx.com/products/rx-10045.asp2013.
85. Hong W, Yan S. Engineering Streptomyces tenebrarius to synthesize single component of carbamoyl tobramycin. Lett Appl Microbiol. 55(1), 33-9 (2012).
86. Wang H, Pang B, Li Y, et al. Dexamethasone has variable effects on mesenchymal stromal cells. Cytotherapy. 14(4), 423-30 (2012).
87. Kabra B. Topical ophthalmic compositions containing tobramycin and dexamethasone. US20107795316 (2010).
88. Wong B. JAK kinase inhibitors and their uses. US20060270694 (2006).
89. Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 183(3), 2183-92 (2009).
90. Barnes TM, Hou J, King BM. Chimeric IL-1 receptor type I agonists and antagonists. WO2012016203 (2012).
91. Furfine ES, Hou J, Collins K, et al., editors. EBI-005: an Interleukin-1 Receptor Inhibitor Designed for the Treatment of Dry Eye Syndrome, 2012 Poster: 2340/A3572012.
92. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 9(2), R28 (2007).
93. Fel A, Aslangul E, Le Jeunne C. (Eye and corticosteroid's use). Presse Med. 41(4), 414-21 (2012).
94. Carracedo G, Peral A, Pintor J. Diadenosine polyphosphates in tears of Sjogren syndrome patients. Invest Ophthalmol Vis Sci. 51(11), 5452-9 (2010).
95. Pintor J. (A molecular marker for dry eye). Arch Soc Esp Oftalmol. 82(3), 129-30 (2007).
96. McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Surv Ophthalmol. 57(4), 293-316 (2012).
97. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 151(5), 792-8 e1 (2011).